TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01630083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolbetuximab
Description: Two different formats of zolbetuximab, comprising different strengths, to be provided. Vials contained 22 mg or 105 mg of zolbetuximab. Prior to administration, zolbetuximab will be reconstituted with 1.1 mL (22 mg zolbetuximab vials) or 5.0 mL (105 mg zolbetuximab vials) water for injection, which will result in a concentration of 20 mg/mL zolbetuximab. The extractable volume per vial will be 1 mL (for 22 mg zolbetuximab vials) or 5 mL (for 105 mg zolbetuximab vials). The reconstituted solution will be further diluted with sodium chloride 0.9% to a final concentration of 2 mg/mL zolbetuximab. Zolbetuximab will be administered as an intravenous infusion over 2 to 3 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolbetuximab
Description: Two different formats of zolbetuximab, comprising different strengths, to be provided. Vials contained 22 mg or 105 mg of zolbetuximab. Prior to administration, zolbetuximab will be reconstituted with 1.1 mL (22 mg zolbetuximab vials) or 5.0 mL (105 mg zolbetuximab vials) water for injection, which will result in a concentration of 20 mg/mL zolbetuximab. The extractable volume per vial will be 1 mL (for 22 mg zolbetuximab vials) or 5 mL (for 105 mg zolbetuximab vials). The reconstituted solution will be further diluted with sodium chloride 0.9% to a final concentration of 2 mg/mL zolbetuximab. Zolbetuximab will be administered as an intravenous infusion over 2 to 3 hours.
Study: NCT04572243

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to lorcaserin oral tablet, administered as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin
Description: Lorcaserin oral tablet, administered as oral suspension.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lorcaserin
Description: Lorcaserin oral tablet, administered as oral suspension.
Study: NCT01635530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline: 100mg tablet two times per day, four weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: 2 g intravenous once a day, three weeks
Study: NCT03381586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Subjects randomized to Group A (n=8) will receive ALT-803 at a concentration of 1.0 mg/mL and subjects randomized to Group B (n=8) will receive ALT-803 at a concentration of 2.0 mg/mL. Subjects will receive a single 10 µg/kg subQ dose of ALT-803 on Day 1 of study period 1. After a rest period, subjects will receive a single 20 µg/kg subQ dose of ALT-803 on Day 1 of study period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Subjects randomized to Group A (n=8) will receive ALT-803 at a concentration of 1.0 mg/mL and subjects randomized to Group B (n=8) will receive ALT-803 at a concentration of 2.0 mg/mL. Subjects will receive a single 10 µg/kg subQ dose of ALT-803 on Day 1 of study period 1. After a rest period, subjects will receive a single 20 µg/kg subQ dose of ALT-803 on Day 1 of study period 2.
Study: NCT00721955

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Placebo
Description: Inhaled loxapine Placebo, may repeat after 2 hours x 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled loxapine 5 mg
Description: Inhaled Staccato loxapine 5 mg, may repeat after 2 hours x 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled loxapine 10 mg
Description: Inhaled Staccato loxapine 10 mg, may repeat after 2 hours x 2
Study: NCT03024268

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Figulla Flex Occluder (Occlutech)
Description: Interventional closure of the iASD with an Figulla Flex Occluder (Occlutech)
Study: NCT02339038

Intervention type: DRUG
Group type: OTHER
Intervention: Ledipasvir 90 mg and Sofosbuvir 400 mg
Description: Ledipasvir 90 mg and Sofosbuvir 400 mg fixed dose combination as per standard of care treatment guidelines
Study: NCT03646162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veru-944
Description: Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veru-944
Description: Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01887158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisacodyl
Study: NCT01903057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: azithromycin
Study: NCT02970812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Muscle Stimulation
Description: Participants were under EMS 5 times a week for 12 weeks. Pads were applied on participants' abdomen, rectus abdominis and external oblique abdominal muscle areas without any recent wound, infection, scar, and warts while lie on their back.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Participants were under TENS 5 times a week for 12 weeks. Pads were applied on participants' abdomen, rectus abdominis and external oblique abdominal muscle areas without any recent wound, infection, scar, and warts while lie on their back.
Study: NCT02339675

Intervention type: OTHER
Group type: OTHER
Intervention: conventional MS rehabilitation
Description: assessment pre and post conventional MS rehabilitation
Study: NCT00049283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo neck dissection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT03434886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CFView
Description: Registry patient portal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CFView
Description: Registry patient portal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CF educational videos
Description: CF educational videos

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CF educational videos
Description: CF educational videos
Study: NCT02658188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8825
Description: Oral
Study: NCT01757496

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cough Assist
Study: NCT01020539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVHD Prophylaxis
Description: Can be FK506 (Tacrolimus/Prograf®), mycophenolate mofetil ((MMF)/Cellcept®), or methotrexate (MTX, amethopterin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Dose Escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Unrelated Donors only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: JMML patients only
Study: NCT00410436

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise
Description: Subjects demonstrating adequate compliance during the run-in period will then be randomized in equal numbers to Resistance Training (R) 3X/week progressing to 3 sets, 8 repetitions of 8 exercises at the maximum load that can be lifted 8 times in a controlled manner, maintaining proper form (8RM), or waiting-list control (C).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Subjects demonstrating adequate compliance during the run-in period will then be randomized in equal numbers to Resistance Training (R) 3X/week progressing to 3 sets, 8 repetitions of 8 exercises at the maximum load that can be lifted 8 times in a controlled manner, maintaining proper form (8RM), or waiting-list control (C).
Study: NCT01746069

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quit smoking combined cessation programme
Description: Support sms messages to patient's mobile phone and health advice

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: health advice
Description: routine clinical practice
Study: NCT02184442

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAVR Implantation with SAPIEN XT
Description: Inoperable operable patients requiring the transcatheter aortic heart valve replacement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAVR Implantation with SAPIEN
Description: Inoperable operable patients requiring the transcatheter aortic heart valve replacement
Study: NCT01473784

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transoral robotic surgery
Description: Undergo TORS using the Da Vinci Robotic Surgical System

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality of life assessment
Description: After surgery regular clinical assessments will be scheduled to see how the patient is doing. Patients will be asked to answer a quality of life assessment as part of the study. If patients are unable to come to the Ohio State University Medical Center for a physician appointment they will be contacted via phone or mailed a questionnaire to complete.
Study: NCT05324787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Grency venous stent system
Description: Venous stent implantation during the index procedure
Study: NCT01095965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education
Description: Group education on a bi-weekly basis for eight weeks plus written education materials, followed by monthly group problem solving meetings till one year.
Study: NCT00912873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% Ropivacaine
Description: Ropivacaine 0.1% will be administered via the perineural catheter as follows: Basal Rate (12mL/h); Basal Dose (12 mg/h); Bolus Volume (4 mL); Bolus Dose (4 mg); Lockout Duration (30 min); Maximum Dose (20 mg/h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.4% Ropivacaine
Description: Ropivacaine 0.1% will be administered via the perineural catheter as follows: Basal Rate (3 mL/h); Basal Dose (12 mg/h); Bolus Volume (1 mL); Bolus Dose (4 mg); Lockout Duration (30 min); Maximum Dose (20 mg/h)
Study: NCT01778621

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture(Hwato®)
Description: acupuncture using 4cm long disposable stainless steel hair-thin needles manufactured by Suzhou medical appliance factory (China).
Study: NCT00872287

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Cholecystectomy
Description: Four ports classic laparoscopic cholecystectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SILS
Description: Single transumbilical incision laparoscopic cholecystectomy
Study: NCT00189878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate (drug)
Description: Methotrexate 10 to 15 mg weekly for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsules
Description: 4-6 placebo capsules - identical to capsules containing methotrexate
Study: NCT04330339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Fasting
Study: NCT00677300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400mg P.O. (orally) twice daily for 48 weeks
Study: NCT02391623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06427878
Description: PF-06427878 will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=8).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06427878
Description: PF-06427878 will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=8).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06427878
Description: PF-06427878 will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=8).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=2).
Study: NCT01903057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ivermectin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albendazole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: albendazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT00677300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: 800 mg P.O. (orally) once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir
Description: 800 mg P.O. (orally) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: 100mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir/Emtricitabine
Description: 300 mg/200 mg P.O. (orally) once daily
Study: NCT04192838

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic incisional ventral hernia repair
Description: Laparoscopic repair of incisional ventral hernias (5-15 cm) with adouble-layer polypropylene- expanded polytetrafluoroethylene (ePTFE) mesh.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open incisional ventral hernia repair
Description: Standard polypropylene mesh was positioned as an inlay, or as an onlay over the external oblique fascia (i.e., subcutaneously), as preferred by the operating team. The mesh was fixed with absorbable stitches. Drains were usually placed.
Study: NCT01018771

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Actifuse ABX
Description: bone graft to be used in posterolateral instrumented lumbar fusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: INFUSE, plus Mastergraft granules
Description: bone graft to be used in posterolateral instrumented lumbar fusion
Study: NCT02956863

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Description: Osteopathic manipulative treatment delivered on pragmatic way.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Exercise for stretching and strength for neck muscles
Study: NCT02018679

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Er:YAG AFL-PDT
Description: AFL was performed using a 2940-nm Er:YAG ablative fractional laser (Joule, Sciton Inc., CA, UA) at 550-600 µm ablation in depth, level 1 coagulation, 22% treatment density, and a single pulse. Immediately afterwards, a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2.
Study: NCT01903057

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02039635

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng
Description: Given Orally

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given Orally
Study: NCT04223349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093
Description: JNJ-70033093 capsules will be administered orally .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093
Description: JNJ-70033093 capsules will be administered orally .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093
Description: JNJ-70033093 capsules will be administered orally .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093
Description: JNJ-70033093 capsules will be administered orally .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093
Description: JNJ-70033093 capsules will be administered orally .
Study: NCT02018679

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MAL-PDT
Description: a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2. Areas which were scheduled to receive MAL-PDT received the second treatment 7 days later.
Study: NCT00637156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRESTIGE LP device at two adjacent levels
Description: PRESTIGE LP is a prosthetic device intended to replace a damaged disc in the cervical spine and intended to act as an intervertebral body spacer rather than a fusion device. It is inserted using an anterior surgical approach.

Intervention type: DEVICE
Group type: OTHER
Intervention: Bi-level fusion with ATLANTIS Cervical Plate System
Description: Bi-level anterior cervical fusion procedure involving cortical ring allograft and the ATLANTIS Cervical Plate System.
Study: NCT01407614

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: external lumbar drainage (ELD) of cerebrospinal fluid
Description: Patients were randomized for external lumbar drainage of cerebrospinal fluid or standard treatment of a subarachnoid hemorrhage alone. External drainage was started within 96 hours of initial subarachnoid hemorrhage during 7 days at a maximum of 5-10 ml/hour.
Study: NCT02391623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06427878
Description: PF-06427878 will be administered as an extemporaneously prepared solution every 12 hours for 14 days (n=8).
Study: NCT04223349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093
Description: JNJ-70033093 capsules will be administered orally .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093
Description: JNJ-70033093 capsules will be administered orally .
Study: NCT02391623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days (n=2).
Study: NCT01205191

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cell-phone supported CBT
Description: Cognitive behavioural therapy provided with all-time (ubiquitous) support by cell phone applications

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CBT with digital audio player support
Description: Cognitive behavioural therapy provided with access to a digital audio player with self-administered materials for stress management and relaxation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: CBT for anxiety disorders
Study: NCT02675101

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole Nuts
Description: Participants will be advised on maintaining an iso-caloric diet. Aside consuming nuts, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Both walnuts and almonds will be provided to participants in the whole nut study arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olestra: Fat Free Pringles
Description: Participants will be advised on maintaining an iso-caloric diet. Aside consuming fat free potato crisps, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Fat Free Pringles will be provided to participants in the olestra study arm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vegetable Oil: Original Pringles
Description: Participants will be advised on maintaining an iso-caloric diet. Aside consuming potato crisps, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Original Pringles will be provided to participants in the vegetable oil study arm.